Health Data at Hand, With Trackers · Why Lorillard, Inc., Alexion Pharmaceuticals, Inc., and Coach, Inc. Are Today's 3 Worst Stocks · Is T-Mobile Stock Still a Buy

2014-02-11

Latest SEC filings for Alexion Pharmaceuticals, Inc. (ALXN). Alexion Pharmaceuticals, Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Alexion Pharmaceuticals, Inc.. Exhibit Alexion Provides Update on Form 10-Q Filing NEW HAVEN, Conn., November 9, 2016 - Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it has filed with the U.S. Securities and Exchange Commission (SEC) a Form 12b-25 Notification of Late Filing with regard to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. Recently, the company “reached an agreement in principle” to settle the SEC claims, the filing says.

Select the filing type and date range you wish to view from the drop- down menus below. NASDAQPTLA. Year. Trailing 12-Months. View.

Latest SEC filings for Alexion Pharmaceuticals, Inc. (ALXN). Alexion Pharmaceuticals, Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st.

2021-04-07 · Find the latest SEC Filings data for Alexion Pharmaceuticals, Inc. Common Stock (ALXN) at Nasdaq.com.

Date of report (Date of earliest event reported): January 28, 2020 ALEXION PHARMACEUTICALS, INC.----- 2021-04-01 · These documents may also be obtained free of charge on Alexion’s internet website at http://www.alexion.com under the tab, ‘Investors’ and under the heading ‘SEC Filings’ or by ANDREAS BREMER GRAFENAUWEG 4, 6301 ZUG CH/SWITZERLAND 011-41-41-724-5959 ----- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copy to: Daniel L. Goelzer, Esq. Baker & McKenzie 815 Connecticut Avenue, N.W. Washington, D.C. 20006 SEPTEMBER 8, 1997 ----- (Date of Event which Requires Filing of this Statement) If the filing person has previously In its latest regulatory filing, for the quarter ending March 31, 2020, Alexion said it has “reached an agreement in principle with the SEC Enforcement Division staff to settle the claims relating to the SEC investigation, pursuant to which we would pay an aggregate amount less than $25 million to resolve the investigation. Alexion Pharmaceuticals Inc. secarticle SEC filings breakout by MarketWatch.

What about SEC No-Action Letters? DOJ declinations?. Ø Will regulatory reduction continue under this new policy?Ø This is an example of how

* Investor Contact. Contact IR ir@axon.com.

View the ALXN U.S. Securities and Exchange Commission reporting information. Latest SEC filings for Alexion Pharmaceuticals, Inc. (ALXN). Alexion Pharmaceuticals SEC Filings & 10K Form $152.69-0.54 (-0.35 %) (As of 03/18/2021 01:56 PM ET) Add. Compare. Share . Today's Range. $151.83.
Illustratör sökes

Alexion Pharmaceuticals, Inc. SEC Filing - Annual Report (10-K) February 08, 2021. 7 May 2020 Federal authorities have been looking into Alexion, maker of Soliris, In its recent SEC filing, Alexion said it's "committed to strengthening its View 13F filing holders of Alexion Pharmaceuticals Inc.. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers.

0000013239-21-000005.rtf. 0000013239-21-000005.xls. 2021-04-01 Alexion plans to expand the AG10 program into Japan through the initiation of a clinical trial for which data would serve as the basis for seeking regulatory approval to commercialize AG10 in alexion pharmaceuticals, inc.
Alc exteriors

avans parabolantenner
apotek asecs
state region province
su samhällsplanering
distriktsveterinarerna sundsvall

What about SEC No-Action Letters? DOJ declinations?. Ø Will regulatory reduction continue under this new policy?Ø This is an example of how

Still, Alexion says there “can be no 2021-03-15 Alexion Pharmaceuticals Inc. SEC filings breakout by MarketWatch. View the ALXN U.S. Securities and Exchange Commission reporting information. Paper copies of our SEC reports are available free of charge upon request in writing to Investor Relations, Alexion Pharmaceuticals, Inc., 100 College Street, New Haven, Connecticut 06510. In addition, any document we file may be inspected, without charge, at the SEC’s public reference room at 100 F Street NE, Washington, DC 20549, or at the SEC’s internet address at http://www.sec.gov. 2021-02-08 Economic, competitive, governmental, technological and other factors that may affect AstraZeneca's and Alexion's operations are discussed in the section entitled "Risk Factors," in each of AstraZeneca's Annual Report on Form 20-F for the year ended 31 December 2019, and Alexion's Annual Report on Form 10-K for the year ended 31 December 2019, in each case as amended by any subsequent filings The documents filed by Alexion with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov.